Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H31N5O2 |
Molecular Weight | 385.5031 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1CC2(CCCC2)CC(=O)N1CCCCN3CCN(CC3)C4=NC=CC=N4
InChI
InChIKey=QWCRAEMEVRGPNT-UHFFFAOYSA-N
InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2
Molecular Formula | C21H31N5O2 |
Molecular Weight | 385.5031 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Buspirone is the first of a new class of anxioselective agents, the azaspirodecanediones. Animal studies have suggested antianxiety activity and the absence of abuse potential. Behavioural, electrophysiological and receptor binding experiments gradually led to the idea that buspirone owes much of its anxiolytic activity to its ability to attenuate central 5-hydroxytryptamine neurotransmission. In vitro preclinical studies have shown that buspirone has a high affinity for serotonin (5-HT1A) receptors. Some studies do suggest that buspirone may have indirect effects on other neurotransmitter systems. Buspirone differs from typical benzodiazepine anxiolytics in that it does not exert anticonvulsant or muscle relaxant effects. It also lacks the prominent sedative effect that is associated with more typical anxiolytics. The drug was approved by FDA for the treatment of anxiety.
CNS Activity
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
[Efficacy and withdrawal of clobazam, lorazepam and buspirone in the treatment of anxiety disorders]. | 1996 Nov-Dec |
|
Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. | 1999 Jun |
|
5-HT1A receptor agonists buspirone and gepirone attenuate apomorphine-induced aggressive behaviour in adult male Wistar rats. | 2000 Dec |
|
Possible serotonin syndrome associated with buspirone added to fluoxetine. | 2000 Jul-Aug |
|
Cerebellar Ataxia. | 2000 May |
|
Effects of serotoninergic drugs on tremor induced by physostigmine in rats. | 2000 May |
|
Involvement of 5-hydroxytryptamine(1A) receptors in nicotine-induced tail tremor in rats. | 2000 Nov 10 |
|
Controversies in dyspepsia. | 2001 |
|
Separation anxiety disorder in children and adolescents: epidemiology, diagnosis and management. | 2001 |
|
Contemporary management of comorbid anxiety and depression in geriatric patients. | 2001 |
|
New developments in the pharmacotherapy of alcohol dependence. | 2001 |
|
Synthesis and pharmacological evaluation of aryl/heteroaryl piperazinyl alkyl benzotriazoles as ligands for some serotonin and dopamine receptor subtypes. | 2001 Apr |
|
Molecular dynamics of buspirone analogues interacting with the 5-HT1A and 5-HT2A serotonin receptors. | 2001 Apr |
|
Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. | 2001 Aug |
|
Ataxia from lithium toxicity successfully treated with high-dose buspirone: a single-case experimental design. | 2001 Aug |
|
Effect of nonnicotine pharmacotherapy on smoking behavior. | 2001 Dec |
|
Extracellular serotonin is enhanced in the striatum, but not in the dorsal hippocampus or prefrontal cortex, in rats subjected to an operant conflict procedure. | 2001 Feb |
|
Acute hypokalemic paralysis associated with long-term lithium therapy. | 2001 Feb |
|
Citalopram-induced bruxism. | 2001 Feb |
|
Treatment of the agitation of late-life psychosis and Alzheimer's disease. | 2001 Jan |
|
Recovery from chronic fatigue syndrome associated with changes in neuroendocrine function. | 2001 Jan |
|
Pharmacokinetics of buspirone extended-release tablets: a single-dose study. | 2001 Jul |
|
Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem. | 2001 Jul |
|
An investigation of the mechanisms responsible for acute fluoxetine-induced anxiogenic-like effects in mice. | 2001 Jun |
|
Discriminative stimulus properties of indorenate in a conditioned taste aversion paradigm. | 2001 Mar |
|
Generalized anxiety disorder in children and adolescents. | 2001 Mar |
|
Pharmacologic treatment of generalized anxiety disorder. | 2001 Mar |
|
S 14506: novel receptor coupling at 5-HT(1A) receptors. | 2001 Mar |
|
Conformational analysis and pharmacophore design for selected 1-(2-pyrimidinyl)piperazine derivatives with sedative-hypnotic activity. | 2001 Mar-Apr |
|
Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. | 2001 May |
|
5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential. | 2001 May 25 |
|
Neuropharmacological analysis of the role of the serotoninergic system in forming hyperalgesia in neurotic rats. | 2001 May-Jun |
|
Acoustic startle, conditioned startle potentiation and the effects of 8-OH-DPAT and buspirone in rats selectively bred for differences in 8-OH-DPAT-induced hypothermia. | 2001 Nov |
|
Quantifying the 5-HT1A agonist action of buspirone in man. | 2001 Nov |
|
Astrocyte-mediated trophic support of developing serotonin neurons: effects of ethanol, buspirone, and S100B. | 2001 Nov 26 |
|
The effect of glucocorticoids on the anxiolytic efficacy of buspirone. | 2001 Oct |
|
Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. | 2001 Sep |
|
Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the rat medial frontal cortex. | 2002 Apr |
|
Olfactory-mediated fear-potentiated startle. | 2002 Feb |
|
Bupropion-induced acute dystonia. | 2002 Feb |
|
Light-enhanced startle: further pharmacological and behavioral characterization. | 2002 Jan |
|
Effect of drug proportion and mixing time on the content uniformity of a low dose drug in a high shear mixer. | 2002 Jan |
|
The stimulus effect of 5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline is similar to that of cocaine but different from that of amphetamine. | 2002 Jan-Feb |
|
Contact leukoderma caused by buspirone patches. | 2002 Mar |
Sample Use Guides
The recommended initial dose is 15 mg daily (7.5 mg b.i.d.). To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day, as needed. The maximum daily dosage should not exceed 60 mg per day. In clinical trials allowing dose titration, divided doses of 20 mg to 30 mg per day were commonly employed.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Oct 22 00:21:21 UTC 2019
by
admin
on
Tue Oct 22 00:21:21 UTC 2019
|
Record UNII |
TK65WKS8HL
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN05BE01
Created by
admin on Tue Oct 22 00:21:21 UTC 2019 , Edited by admin on Tue Oct 22 00:21:21 UTC 2019
|
||
|
LIVERTOX |
129
Created by
admin on Tue Oct 22 00:21:21 UTC 2019 , Edited by admin on Tue Oct 22 00:21:21 UTC 2019
|
||
|
WHO-ATC |
N05BE01
Created by
admin on Tue Oct 22 00:21:21 UTC 2019 , Edited by admin on Tue Oct 22 00:21:21 UTC 2019
|
||
|
NCI_THESAURUS |
C28197
Created by
admin on Tue Oct 22 00:21:21 UTC 2019 , Edited by admin on Tue Oct 22 00:21:21 UTC 2019
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
36505-84-7
Created by
admin on Tue Oct 22 00:21:21 UTC 2019 , Edited by admin on Tue Oct 22 00:21:21 UTC 2019
|
PRIMARY | |||
|
M2777
Created by
admin on Tue Oct 22 00:21:21 UTC 2019 , Edited by admin on Tue Oct 22 00:21:21 UTC 2019
|
PRIMARY | Merck Index | ||
|
CHEMBL49
Created by
admin on Tue Oct 22 00:21:21 UTC 2019 , Edited by admin on Tue Oct 22 00:21:21 UTC 2019
|
PRIMARY | |||
|
2477
Created by
admin on Tue Oct 22 00:21:21 UTC 2019 , Edited by admin on Tue Oct 22 00:21:21 UTC 2019
|
PRIMARY | |||
|
SUB05992MIG
Created by
admin on Tue Oct 22 00:21:21 UTC 2019 , Edited by admin on Tue Oct 22 00:21:21 UTC 2019
|
PRIMARY | |||
|
36
Created by
admin on Tue Oct 22 00:21:21 UTC 2019 , Edited by admin on Tue Oct 22 00:21:21 UTC 2019
|
PRIMARY | |||
|
1827
Created by
admin on Tue Oct 22 00:21:21 UTC 2019 , Edited by admin on Tue Oct 22 00:21:21 UTC 2019
|
PRIMARY | RxNorm | ||
|
D002065
Created by
admin on Tue Oct 22 00:21:21 UTC 2019 , Edited by admin on Tue Oct 22 00:21:21 UTC 2019
|
PRIMARY | |||
|
253-072-2
Created by
admin on Tue Oct 22 00:21:21 UTC 2019 , Edited by admin on Tue Oct 22 00:21:21 UTC 2019
|
PRIMARY | |||
|
BUSPIRONE
Created by
admin on Tue Oct 22 00:21:21 UTC 2019 , Edited by admin on Tue Oct 22 00:21:21 UTC 2019
|
PRIMARY | |||
|
C62013
Created by
admin on Tue Oct 22 00:21:21 UTC 2019 , Edited by admin on Tue Oct 22 00:21:21 UTC 2019
|
PRIMARY | |||
|
3456
Created by
admin on Tue Oct 22 00:21:21 UTC 2019 , Edited by admin on Tue Oct 22 00:21:21 UTC 2019
|
PRIMARY | |||
|
DB00490
Created by
admin on Tue Oct 22 00:21:21 UTC 2019 , Edited by admin on Tue Oct 22 00:21:21 UTC 2019
|
PRIMARY | |||
|
36505-84-7
Created by
admin on Tue Oct 22 00:21:21 UTC 2019 , Edited by admin on Tue Oct 22 00:21:21 UTC 2019
|
PRIMARY | |||
|
36505-84-7
Created by
admin on Tue Oct 22 00:21:21 UTC 2019 , Edited by admin on Tue Oct 22 00:21:21 UTC 2019
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET->PARTIAL AGONIST | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||